Carl Figdor

from Wikipedia, the free encyclopedia
Carl Figdor (2006)

Carl Gustav Figdor (born June 26, 1953 in 's-Hertogenbosch ) is a Dutch immunologist who specializes in tumor immunology and cancer immunotherapy.

Figdor studied biology at the University of Utrecht , graduated in 1979 and received his doctorate in 1982 at the University of Amsterdam at the Netherlands Cancer Research Institute. From 1985 he had his own research group in tumor immunology there. In 1992 he became professor for cell biophysics at the University of Twente and in 1994 he became professor and head of tumor immunology at the Medical Faculty (UMC) of Radboud University Nijmegen . From 2001 to 2010 he was the first scientific director of the Nijmegen Center for Molecular Life Sciences (NCMLS).

In 1989 he discovered that LFA- 1, a protein that is important for the binding of white blood cells to vessel walls, has different conformations and must be activated for binding to its ligand ICAM-1.

In 2000 he and Yvette van Kooyk discovered the lectin receptor DC-sign and its important role in various pathogens and as an adhesion receptor. For example, it plays an important role in the binding to and uptake of the HI virus in dendritic cells of the immune system, via which the virus is also spread in the body. Dendritic cells play an important role in that they present antigens, for example from pathogens, to the cells of the immune system. He developed methods to follow the migration of dendritic cells in vivo in the body of patients using MRI and scintigraphy . He investigates the role of lectin-like receptors in the uptake of antigens in cells of the immune system and the role of the cytoskeleton in the migration and adhesion of dendritic cells. He is also working on improved imaging methods for cell receptors on cell surfaces.

He pioneered the use of dendritic cells in cancer immunotherapy. These are taken from the patient's body, modified in the laboratory for use against cancer and then re-injected into the patient. Through his development of new imaging methods for tracking dendritic cells in the body, he was also able to show that this form of tumor immunotherapy was only effective in about half of the patients. Together with organic chemists (Alan Hest, Jan van Rowan) he is researching methods of producing immune cells against cancer in the laboratory (2012).

He is a member of the Royal Netherlands Academy of Sciences (2008) and the Academia Europaea (2012). In 1999 he received the van Loghum Prize in Immunology, the Spinoza Prize in 2006 , the KWO Prize of the Dutch Cancer Society (KWF Kankerbestrijding) in 2009 and an Advanced Grant from the European Research Council (ERC) in 2011 .


Besides the works cited in the footnotes.

  • with Rene de Waal Malefyt, John Abrams, Bruce Bennett and Jan E de Vries: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. In: The Journal of Experimental Medicine. Volume 174, 1991, pp. 1209-1220.
  • with René de Waal Malefyt, JBAG Haanen, Hergen Spits, Maria-Grazia Roncarolo, Anje Te Velde, Karen Johnson, Rob Kastelein, Hans Yssel and Jan E De Vries: Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen -specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. In: The Journal of Experimental Medicine. Volume 174, 1991, pp. 915-924.
  • with Yvette van Kooyk and Gosse J Adema: C-type lectin receptors on dendritic cells and Langerhans cells. In: Nature Reviews Immunology. Volume 2, 2002, pp. 77-84.
  • with I. Jolanda M de Vries, W. Joost Lesterhuis and Cornelis JM Melief: Dendritic cell immunotherapy: mapping the way. In: Nature Medicine. Volume 10, 2004, pp. 475-480.
  • with PJ Tacken, W. Ginter, L. Berod, LJ Cruz, B. Joosten, T. Sparwasser and A. Cambi: Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross -presentation . Blood, Vol. 118, 2011, pp. 4111-4119.
  • with LJ Cruz, PJ Tacken and R. Fokkink: The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. In: Biomaterials. Volume 32, 2011, pp. 6791-6803.
  • with WJ Lesterhuis, IJ de Vries, G. Schreibelt, AJ Lambeck, EH Aarntzen, JF Jacobs, NM Scharenborg, MW van de Rakt, AJ de Boer, S. Croockewit, MM van Rossum, R. Mus, WJ Oyen, OC Boerman , S. Lucas, GJ Adema and CJ Punt: Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. In: Clin Cancer Res. Volume 17, 2011, pp. 5725-5735.
  • with M. Srinivas, EH Aarntzen, JW Bulte, WJ Oyen, A. Heerschap and IJ de Vries: Imaging of cellular therapies. In: Adv Drug Deliv Rev. Volume 62, 2010, pp. 1080-1093.
  • with G. Schreibelt, D. Benitez-Ribas, D. Schuurhuis, AJ Lambeck, M. van Hout-Kuijer, N. Schaft, CJ Punt, GJ Adema and IJ de Vries: Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. In: Blood. Volume 116, 2010, pp. 564-574.

Web links

Individual evidence

  1. Y. Van Kooyk, P. Van de Wiel van Kemenade, P. Neither, TW Kuijpers, CG Figdor: Enhancement of LFA-1-mediated cell adhesion by triggering through CD2 or CD3 on T lymphocytes. In: Nature. Volume 342, 1989, pp. 811-813.
  2. TB Geijtenbeek, DS Kwon, R. Torensma, SJ van Vliet, GC van Duijnhoven, J. Middel, IL Cornelissen, HS Nottet, VN Kewal-Ramani, DR Littman, CG Figdor, Y. van Kooyk: DC-SIGN, a dendritic cell-specific HIV-1 binding protein that enhances trans-infection of T cells. In: Cell. Volume 100, 2000, pp. 587-597.
  3. TB Geijtenbeek, R. Torensma, SJ van Vliet, GC van Duijnhoven, GJ Adema, Y. van Kooyk, CG Figdor: Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. In: Cell. Volume 100, 2000, pp. 575-585.
  4. Teunis BH Geijtenbeek, Daniëlle JEB Krooshoop, Diederik A Bleijs, Sandra J van Vliet, Gerard CF van Duijnhoven, Valentine Grabovsky, Ronen Alon, Carl G Figdor, Yvette van Kooyk: DC-SIGN – ICAM-2 interaction mediates dendritic cell trafficking. In: Nature Immunology. Volume 1, 2000, pp. 353-357.
  5. Anneke Engering, Teunis BH Geijtenbeek, Sandra J van Vliet, Mietske Wijers, Ellis van Liempt, Nicolas Demaurex, Antonio Lanzavecchia , Jack Fransen, Carl G Figdor, Vincent Piguet, Yvette van Kooyk: The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. In: The Journal of Immunology. Volume 168, 2002, pp. 2118-2126.
  6. ^ I. Jolanda M de Vries, W. Joost Lesterhuis, Jelle O Barentsz, Pauline Verdijk, J. Han van Krieken, Otto C Boerman, Wim JG Oyen, Johannes J Bonenkamp, ​​Jan B Boezeman, Gosse J Adema, Jeff WM Bulte, Tom WJ Scheenen, Cornelis JA Punt, Arend Heerschap, Carl G Figdor: Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. In: Nature Biotechnology. Volume 23, 2005, pp. 1407-1413.
  7. ^ Portrait at the NWO for the Spinozapreis 2006
  8. ^ Carl Figdor, world-class immunologist. ( Memento from April 5, 2014 in the web archive ) Portrait at Radboud University 2013
  9. ^ Membership directory: Carl Gustav Figdor. Academia Europaea, accessed October 20, 2017 .